Literature DB >> 23147518

Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis.

Annalisa Berzigotti1, Eva Erice, Rosa Gilabert, Enric Reverter, Juan G Abraldes, Juan Carlos García-Pagan, Jaime Bosch.   

Abstract

OBJECTIVES: Cardiovascular risk factors (CVRF) lead to systemic endothelial dysfunction. It has been suggested that in cirrhosis, cardiovascular risk is low and systemic endothelial function is enhanced. However, there is no prospective study evaluating the relationship between cardiovascular risk and systemic endothelial function in cirrhosis, which was investigated here.
METHODS: In 47 patients with cirrhosis (33 males; median Child-Pugh score 8; median age 55 years), we evaluated: laboratory parameters, hepatic and systemic hemodynamics, CVRF, 10-year global cardiovascular risk by Framingham score, and presence of carotid plaques. Systemic endothelial dysfunction was investigated non-invasively by flow-mediated dilatation (FMD) of the brachial artery by ultrasound and defined as FMD <10%.
RESULTS: Cardiovascular risk (median 7%) was low in 25%, moderate in 26%, moderately high in 40%, and high in 9%. Fifty-three percent of patients had systemic endothelial dysfunction. Systemic endothelial dysfunction (low FMD) increased in parallel with CV risk (linear trend P=0.039) and was higher in patients overweight or obese. Conversely, FMD increased in parallel with Child-Pugh/Mayo Clinic Model for End-stage Liver Disease (MELD) score, bilirubin, serum sodium, plasma renin activity, leukocyte count, platelet count, and with lower arterial pressure, suggesting that enhanced FMD is a feature of advanced liver failure and inflammation. Cardiovascular risk, bilirubin, leukocyte count, and arterial pressure remained independently associated with systemic endothelial dysfunction.
CONCLUSIONS: CV risk was not low in our studied patients with cirrhosis, and systemic endothelial dysfunction was frequent in this population. In cirrhosis, similar to general population, cardiovascular risk impaired systemic FMD, although liver failure attenuated endothelial dysfunction.

Entities:  

Mesh:

Year:  2012        PMID: 23147518     DOI: 10.1038/ajg.2012.362

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

Review 1.  Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.

Authors:  Jose Ignacio Vargas; Marco Arrese; Vijay H Shah; Juan Pablo Arab
Journal:  Curr Gastroenterol Rep       Date:  2017-09

Review 2.  The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.

Authors:  Carlos Moctezuma-Velázquez; Juan G Abraldes; Aldo J Montano-Loza
Journal:  Curr Treat Options Gastroenterol       Date:  2018-06

Review 3.  Treatment of Dyslipidemia in Common Liver Diseases.

Authors:  Elizabeth K Speliotes; Maya Balakrishnan; Lawrence S Friedman; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-21       Impact factor: 11.382

4.  Vascular Age, Metabolic Panel, Cardiovascular Risk and Inflammaging in Patients With Rheumatoid Arthritis Compared With Patients With Osteoarthritis.

Authors:  Gabriel-Santiago Rodríguez-Vargas; Pedro Santos-Moreno; Jaime-Andrés Rubio-Rubio; Paula-Katherine Bautista-Niño; Darío Echeverri; Luz-Dary Gutiérrez-Castañeda; Fabio Sierra-Matamoros; Stephania Navarrete; Anggie Aparicio; Luis Saenz; Adriana Rojas-Villarraga
Journal:  Front Cardiovasc Med       Date:  2022-07-05

5.  Visual quality assessment of the liver graft by the transplanting surgeon predicts postreperfusion syndrome after liver transplantation: a retrospective cohort study.

Authors:  Felix Kork; Alexandra Rimek; Anne Andert; Niklas Jurek Becker; Christoph Heidenhain; Ulf P Neumann; Daniela Kroy; Anna B Roehl; Rolf Rossaint; Marc Hein
Journal:  BMC Anesthesiol       Date:  2018-03-09       Impact factor: 2.217

6.  Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).

Authors:  Alaa Badawi; Giancarlo Di Giuseppe; Paul Arora
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

Review 7.  Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?

Authors:  Pedro Castro; Marta Palomo; Ana Belen Moreno-Castaño; Sara Fernández; Sergi Torramadé-Moix; Georgina Pascual; Julia Martinez-Sanchez; Edward Richardson; Adrián Téllez; Josep M Nicolas; Enric Carreras; Paul G Richardson; Juan José Badimon; Gines Escolar; Maribel Diaz-Ricart
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-07       Impact factor: 3.947

Review 8.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.

Authors:  Cornelius Engelmann; Joan Clària; Gyongyi Szabo; Jaume Bosch; Mauro Bernardi
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

9.  Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study.

Authors:  Francesca Romana Ponziani; Barbara Funaro; Andrea Lupascu; Maria Elena Ainora; Matteo Garcovich; Gianluigi Caracciolo; Alessandro Quadarella; Antonio Nesci; Laura Riccardi; Antonio Gasbarrini; Maurizio Pompili; Maria Assunta Zocco
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

10.  Association of Asymmetric Dimethylarginine and Nitric Oxide with Cardiovascular Risk in Patients with End-Stage Liver Disease.

Authors:  Maro Dragičević; Iva Košuta; Egon Kruezi; Marijana Vučić Lovrenčić; Anna Mrzljak
Journal:  Medicina (Kaunas)       Date:  2020-11-18       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.